

1 **Minutes**
2 **Meeting of the Toxicology Subcommittee**
3 **of the Scientific Advisory Committee**
4 **April 20, 2022**

5 **Department of Forensic Science, Central Laboratory, Classrooms 1 & 2**
6

7 **Subcommittee Members Present**

8 Randall E. Beaty, *Subcommittee Chair*
9 Marc A. LeBeau, Ph.D.
10 Richard P. Meyers
11

12 **Staff Members Present**

13 David A. Barron, Ph.D., Deputy Director
14 James W. Hutchings, Ph.D., Toxicology Program Manager
15 Linda C. Jackson, Director
16 Amy C. Jenkins, Department Counsel
17 Alka B. Lohmann, Director of Technical Services
18 Jessica B. Norton, Legal Assistant
19 Elise Stroble, Grants and Administration Program Manager
20 Rebecca Wagner, Ph.D., Research Section Supervisor
21

22 **Call to Order by Subcommittee Chair**

23 Mr. Beaty called the meeting of the Toxicology Subcommittee (“Subcommittee”) to order at 8:30
24 a.m.
25

26 **Adoption of Agenda**

27 Mr. Beaty advised that the first order of business was the adoption of the draft agenda for the
28 meeting and noted that the agenda was previously shared with the Subcommittee members. Dr.
29 LeBeau made a motion to adopt the agenda, which was seconded by Mr. Meyers and passed by
30 unanimous vote of the Subcommittee.
31

32 **Adoption of Draft Minutes from the October 13, 2021 Subcommittee Meeting**

33 Mr. Beaty noted that the draft minutes from the October 13, 2021 meeting of the Subcommittee
34 were previously shared and asked if there were any proposed changes. Being none, Mr. Meyers
35 made a motion that the minutes be approved, which was seconded by Dr. LeBeau and adopted by
36 unanimous vote.
37

38 **Discussion of Validation Summaries and Plans**

39 In advance of the meeting, the members of the Subcommittee were provided copies of validation
40 summaries for the following methods:
41

- 42 ● Ephedrine Confirmation by Liquid-Liquid Extraction and LCMSMS
 - 43 ● Etizolam Quantitation and Confirmation by Liquid-Liquid Extraction using LCMSMS
- 44

45 Dr. Wagner provided an updated overview of these two method validation summaries, as the
46 Subcommittee had previously approved the plans at the October 2021 meeting. The Subcommittee
47 members provided comments and asked questions, which were answered by Dr. Wagner and Dr.
48 Hutchings.

49
50 Also in advance of the meeting, the members of the Subcommittee were provided validation plans
51 and summaries for the following methods:

- 52
- 53 ● Expansion of the Miscellaneous Base Drugs Quantitation and Confirmation by Solid Phase
54 Extraction Using LCMSMS
 - 55 ● Sertraline in the Miscellaneous Base Drugs Quantitation and Confirmation by Solid Phase
56 Extraction Using LCMSMS
- 57

58 Dr. Wagner provided an overview of the validation plan and summary for each method. After Dr.
59 Wagner summarized each, the Subcommittee members provided comments and asked questions.
60 Mr. Beaty then asked for a motion to close the discussions of all four validation plans and/or
61 summaries. Dr. LeBeau made a motion to close the discussions, which was seconded by Mr.
62 Meyers and passed by unanimous vote of the Subcommittee.

63
64 **Discussion of Verification Plan**
65 In advance of the meeting, the members of the Subcommittee were provided copies of verification
66 plan documentation for the following method:

- 67
- 68 ● Verification Plan of Horse Blood for Opioid and Cocaine Quantitation and Confirmation
69 using LCMSMS
- 70

71 Dr. Wagner provided an overview of the verification plan for Horse Blood for Opioid and Cocaine
72 for Quantitation and Confirmation using LCMSMS. After Dr. Wagner summarized the
73 verification plan, the Subcommittee members discussed the need for a horse blood alternative
74 given the difficulties in securing an economical and unadulterated human blood source for use in
75 case analysis and research. The Subcommittee members questioned what alternatives were
76 considered and expressed interest in the results of the research. If horse blood is demonstrated to
77 be a suitable alternative during the verification, the Subcommittee members discussed the benefits
78 of utilizing human blood as a control when feasible. Following the discussion of the verification
79 plan, Mr. Beaty then asked for a motion to close the discussion of the verification plan. Dr. LeBeau
80 made a motion to close the review, which was seconded by Mr. Meyers and passed by unanimous
81 vote of the Subcommittee.

82
83 **Public Comment**
84 No member of the public was present to provide comment.

85
86 **Adjournment**
87 Mr. Beaty asked for a motion to adjourn the meeting. Dr. LeBeau made a motion to adjourn the
88 meeting, which was seconded by Mr. Meyers and passed by unanimous vote of the Subcommittee.
89 The meeting adjourned at 9:07 a.m.